LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 10

Search options

  1. Article ; Online: Retrospective Investigation of Human Papillomavirus Cervical Infection and Lymphoma Incidence: A Clinical and Pathological Evaluation.

    Gardella, Barbara / Dominoni, Mattia / Pasquali, Marianna Francesca / Gotti, Manuel / Fraticelli, Sara / Lucioni, Marco / Cesari, Stefania / Fiandrino, Giacomo / De Silvestri, Annalisa / Zerbi, Caterina / Lazic, Tanja / Arcaini, Luca / Paulli, Marco / Spinillo, Arsenio

    Gynecologic and obstetric investigation

    2024  Volume 89, Issue 2, Page(s) 95–102

    Abstract: Objective: Human papillomavirus (HPV) persistence is considered the main risk factor for neoplastic progression, and evidence suggests that regulatory T cells play an important role in the failure of viral elimination. Regulatory T cells may be involved ...

    Abstract Objective: Human papillomavirus (HPV) persistence is considered the main risk factor for neoplastic progression, and evidence suggests that regulatory T cells play an important role in the failure of viral elimination. Regulatory T cells may be involved in maintaining a microenvironment favourable for viral persistence and neoplasticity, through a deregulation of the local immune response. The association between altered immune function and the development of chronic infections, cancer (solid and haematological), and autoimmune diseases is documented in the literature. The purpose of this retrospective analysis was to evaluate the possible correlation between HPV cervical infection and lymphoma incidence in women attending colposcopy due to an abnormal Pap smear during a period of 15 years.
    Design: This is a cross-sectional study.
    Participants: We investigated retrospectively the incidence of haematological diseases in women aged 21-84 with an abnormal Pap smear who referred to our centre between 2004 and 2019.
    Setting: This study was conducted at the university hospital.
    Methods: In our analysis, we included women with diagnoses of HL and NHL after the detection of abnormal Pap smears and HPV infections. We excluded patients with a diagnosis of lymphoma preceding the date of the abnormal Pap smear and HPV test.
    Results: We divided the patients into two groups in order to analyse the standard incidence ratio (SIR): HL patients (19/7,064, 0.26%) and NHL patients (22/7,064, 0.31%). In our sample, we reported a significant risk of developing lymphoma compared to the general population, both for HL and NHL disease, at age <45 years. Regarding HL, the SIR of disease in women <45 years was 4.886 (95% CI 2.775-9.6029) and in women between 45 and 59 years was 2.612 (95% CI 0.96-7.108804). On the other hand, for NHL in women <45 years, we reported an SIR of about 3.007 (95%, CI 1.273-7.101575), in women aged 45-59 years, the SIR was 4.291 (95% CI 2.444-7.534399), and in women aged 60-74 years, the SIR was 3.283 (95% CI 1.054-10.22303).
    Limitations: This retrospective analysis was conducted in a single centre in Northern Italy and did not consider all interregional differences existing in the country in terms of HPV genotypes, ethnicity, and population characteristics. Regarding the analysis of SIR for HL and NHL, we did not divide the disease into subtypes because of the small sample of cases. Finally, we considered in our analysis only women with an abnormal Pap smear and not the general population.
    Conclusions: Women with chronic and persistent HPV infections may have a higher relative risk of developing lymphoma. This possible association may be caused by the deregulation of the immune system response against HPV and the failure of viral clearance, especially in younger women.
    MeSH term(s) Humans ; Female ; Middle Aged ; Papillomavirus Infections/complications ; Papillomavirus Infections/epidemiology ; Papillomavirus Infections/diagnosis ; Vaginal Smears ; Retrospective Studies ; Papanicolaou Test ; Uterine Cervical Neoplasms/pathology ; Cross-Sectional Studies ; Papillomaviridae/genetics ; Human Papillomavirus Viruses ; Lymphoma/epidemiology ; Uterine Cervical Dysplasia/pathology ; DNA, Viral/analysis ; Tumor Microenvironment
    Chemical Substances DNA, Viral
    Language English
    Publishing date 2024-01-23
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 800003-7
    ISSN 1423-002X ; 0378-7346
    ISSN (online) 1423-002X
    ISSN 0378-7346
    DOI 10.1159/000535592
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: HCV infection and non-Hodgkin lymphomas: an evolving story.

    Defrancesco, Irene / Zerbi, Caterina / Rattotti, Sara / Merli, Michele / Bruno, Raffaele / Paulli, Marco / Arcaini, Luca

    Clinical and experimental medicine

    2020  Volume 20, Issue 3, Page(s) 321–328

    Abstract: Hepatitis C virus infection represents a global health problem with 3% of population infected worldwide. Several epidemiological studies have shown an increased risk of B cell non-Hodgkin lymphomas in HCV-infected subjects with a wide geographic ... ...

    Abstract Hepatitis C virus infection represents a global health problem with 3% of population infected worldwide. Several epidemiological studies have shown an increased risk of B cell non-Hodgkin lymphomas in HCV-infected subjects with a wide geographic variability. The observation that HCV eradication by antiviral treatment is associated with successful lymphoma response provided the most convincing evidence for the causal role of HCV in lymphoma's development. According to the most accepted model, HCV-driven chronic antigenic stimulation may represent the major stimulus for lymphoma growth. Several evidences have led to recommend antiviral therapy (in the past interferon-based, now the new direct-acting antiviral agents) in the setting of asymptomatic indolent B cell lymphomas not requiring an immediate systemic treatment. The favourable profile of direct-acting antiviral agents supports the HCV eradication also in the setting of HCV-positive diffuse large B cell lymphoma; however, further studies are needed to assess the appropriate timing of these drugs in the treatment of aggressive lymphomas. Multidisciplinary management involving expert hepatologists is highly warranted.
    MeSH term(s) Antiviral Agents/therapeutic use ; Disease Management ; Hepatitis C/complications ; Hepatitis C/drug therapy ; Humans ; Interdisciplinary Communication ; Lymphoma, B-Cell/drug therapy ; Lymphoma, B-Cell/virology
    Chemical Substances Antiviral Agents
    Language English
    Publishing date 2020-02-12
    Publishing country Italy
    Document type Journal Article ; Review
    ZDB-ID 2053018-3
    ISSN 1591-9528 ; 1591-8890
    ISSN (online) 1591-9528
    ISSN 1591-8890
    DOI 10.1007/s10238-020-00615-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection.

    Sciarra, Roberta / Merli, Michele / Cristinelli, Caterina / Lucioni, Marco / Zibellini, Silvia / Riboni, Roberta / Furlan, Daniela / Uccella, Silvia / Zerbi, Caterina / Bianchi, Benedetta / Gotti, Manuel / Ferretti, Virginia Valeria / Varraso, Chiara / Fraticelli, Sara / Lazic, Tanja / Defrancesco, Irene / Mora, Barbara / Libera, Laura / Mazzacane, Alessandro /
    Carpi, Federico / Berliner, Martha / Neri, Giuseppe / Rizzo, Ettore / De Paoli, Federica / Sessa, Fausto / Passamonti, Francesco / Paulli, Marco / Arcaini, Luca

    British journal of haematology

    2024  

    Abstract: Hepatitis C virus (HCV)-associated diffuse large B-cell lymphoma (DLBCL) displays peculiar clinicopathological characteristics, but its molecular landscape is not fully elucidated. In this study, we investigated the clinicopathological and molecular ... ...

    Abstract Hepatitis C virus (HCV)-associated diffuse large B-cell lymphoma (DLBCL) displays peculiar clinicopathological characteristics, but its molecular landscape is not fully elucidated. In this study, we investigated the clinicopathological and molecular features of 54 patients with HCV-associated DLBCL. The median age was 71 years. An underlying marginal zone lymphoma component was detected in 14.8% of cases. FISH analysis showed rearrangements involving BCL6 in 50.9% of cases, MYC in 11.3% and BCL2 in 3.7%. Lymph2Cx-based assay was successful in 38 cases, recognizing 16 cases (42.1%) as ABC and 16 cases as GCB subtypes, while six resulted unclassified. ABC cases exhibited a higher lymphoma-related mortality (LRM). Next-generation sequencing analysis showed mutations in 158/184 evaluated genes. The most frequently mutated genes were KMT2D (42.6%), SETD1B (33.3%), RERE (29.4%), FAS and PIM1 (27.8%) and TBL1XR1 (25.9%). A mutation in the NOTCH pathway was detected in 25.9% of cases and was associated with worst LRM. Cluster analysis by LymphGen classified 29/54 cases within definite groups, including BN2 in 14 (48.2%), ST2 in seven (24.2%) and MCD and EZB in four each (13.8%). Overall, these results indicate a preferential marginal zone origin for a consistent subgroup of HCV-associated DLBCL cases and suggest potential implications for molecularly targeted therapies.
    Language English
    Publishing date 2024-03-05
    Publishing country England
    Document type Journal Article
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.19378
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Systematic screening for SARS-CoV-2 in patients with hematological malignancies on active anticancer treatment in the outpatient setting.

    Varettoni, Marzia / Mangiacavalli, Silvia / Rattotti, Sara / Cartia, Claudio Salvatore / Cavalloni, Chiara / Rossetti, Franca / Ferretti, Virginia Valeria / Bergamini, Fabio / Trotti, Chiara / Fiorelli, Nicolas / Pagani, Giuseppina / Zerbi, Caterina / Ferrari, Jacqueline / Cristinelli, Caterina / Muzzi, Alba / Marena, Carlo / Baldanti, Fausto / Bruno, Raffaele / Arcaini, Luca

    Leukemia & lymphoma

    2021  Volume 62, Issue 13, Page(s) 3311–3312

    MeSH term(s) COVID-19 ; Hematologic Neoplasms/diagnosis ; Hematologic Neoplasms/drug therapy ; Hematologic Neoplasms/epidemiology ; Humans ; Outpatients ; SARS-CoV-2
    Language English
    Publishing date 2021-07-14
    Publishing country United States
    Document type Letter
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2021.1953019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis.

    Defrancesco, Irene / Zibellini, Silvia / Boveri, Emanuela / Frigeni, Marco / Ferretti, Virginia Valeria / Rizzo, Ettore / Bonometti, Arturo / Capuano, Francesca / Candido, Chiara / Rattotti, Sara / Tenore, Annamaria / Picone, Cristina / Flospergher, Elena / Zerbi, Caterina / Bergamini, Fabio / Fabbri, Nicole / Cristinelli, Caterina / Varettoni, Marzia / Paulli, Marco /
    Arcaini, Luca

    Hematological oncology

    2020  Volume 38, Issue 5, Page(s) 689–697

    Abstract: Non-chronic lymphocytic leukemia (non-CLL) clonal B-cell lymphocytosis (CBL) encompasses a heterogeneous group of hematologic disorders that are still poorly understood. To shed light on their biological aspects, we retrospectively analyzed a highly ... ...

    Abstract Non-chronic lymphocytic leukemia (non-CLL) clonal B-cell lymphocytosis (CBL) encompasses a heterogeneous group of hematologic disorders that are still poorly understood. To shed light on their biological aspects, we retrospectively analyzed a highly selected series of 28 patients, who had a clonal B-cell population in the peripheral blood and in the bone marrow, without evidence of lymphoma. Extended targeted next-generation sequencing revealed wide molecular heterogeneity with MYD88 (14%), PDE4DIP (14%), BIRC3 (11%), CCND3 (11%), NOTCH1 (11%), and TNFAIP3 (11%) as the most mutated genes. Mutations of MYD88 were "nonclassic" in most cases. Although some genetic lesions were overlapping with indolent lymphomas, mainly splenic B-cell lymphomas of marginal zone origin and splenic diffuse red pulp small B-cell lymphoma, the genetic profile of our non-CLL CBL series seemed to suggest that various pathways could be involved in the pathogenesis of these disorders, not mirroring any specific lymphoma entity. These data better enlighten the molecular characteristics of non-CLL CBL; however, more efforts are needed in order to improve the diagnostic process, prognostication, and clinical management.
    MeSH term(s) Aged ; Alleles ; Biomarkers, Tumor ; Disease Susceptibility ; Female ; Gene Expression ; Genetic Heterogeneity ; Genetic Predisposition to Disease ; High-Throughput Nucleotide Sequencing ; Humans ; Immunoglobulin Heavy Chains/genetics ; Immunohistochemistry ; Immunophenotyping ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism ; Male ; Middle Aged ; Mutation
    Chemical Substances Biomarkers, Tumor ; Immunoglobulin Heavy Chains
    Language English
    Publishing date 2020-08-19
    Publishing country England
    Document type Journal Article
    ZDB-ID 604884-5
    ISSN 1099-1069 ; 0278-0232
    ISSN (online) 1099-1069
    ISSN 0278-0232
    DOI 10.1002/hon.2784
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders.

    Defrancesco, Irene / Visentini, Marcella / Zibellini, Silvia / Minafò, Ylenia Aura / Rattotti, Sara / Ferretti, Virginia Valeria / Rizzo, Ettore / Varettoni, Marzia / Frigeni, Marco / Pulsoni, Alessandro / Casato, Milvia / Colantuono, Stefania / Rossi, Marianna / Candido, Chiara / Zerbi, Caterina / Bergamini, Fabio / Cristinelli, Caterina / Fabbri, Nicole / Merli, Michele /
    Zuccaro, Valentina / Bruno, Raffaele / Paulli, Marco / Arcaini, Luca

    American journal of hematology

    2021  Volume 96, Issue 6, Page(s) E210–E214

    MeSH term(s) B-Lymphocytes/chemistry ; Cryoglobulinemia/genetics ; Cryoglobulinemia/immunology ; Cryoglobulinemia/mortality ; Cryoglobulinemia/virology ; Follow-Up Studies ; Gene Rearrangement, B-Lymphocyte, Heavy Chain ; Gene Rearrangement, B-Lymphocyte, Light Chain ; Hepacivirus/pathogenicity ; Hepatitis C/complications ; Humans ; Immunoglobulin Variable Region/genetics ; Kaplan-Meier Estimate ; Lymphoma, B-Cell/genetics ; Lymphoma, B-Cell/immunology ; Lymphoma, B-Cell/mortality ; Lymphoma, B-Cell/virology ; Lymphoproliferative Disorders/genetics ; Lymphoproliferative Disorders/immunology ; Lymphoproliferative Disorders/mortality ; Lymphoproliferative Disorders/virology ; Mutation ; Neoplasm Proteins/genetics ; Progression-Free Survival
    Chemical Substances Immunoglobulin Variable Region ; Neoplasm Proteins
    Language English
    Publishing date 2021-04-09
    Publishing country United States
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.26167
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.

    Varettoni, Marzia / Zibellini, Silvia / Boveri, Emanuela / Klersy, Catherine / Candido, Chiara / Rattotti, Sara / Ferretti, Virginia V / Defrancesco, Irene / Mangiacavalli, Silvia / Nizzoli, Maria E / Flospergher, Elena / Zerbi, Caterina / Bergamini, Fabio / Benvenuti, Pietro / Brociner, Marco / Merati, Gabriele / Paulli, Marco / Arcaini, Luca

    British journal of haematology

    2019  Volume 187, Issue 4, Page(s) 441–446

    Abstract: IgM monoclonal gammopathies of undetermined significance (IgM MGUS) are associated with a risk of progression to Waldenström macroglobulinaemia (WM) or other lymphoproliferative disorders (LPD) of 1-2% per year. We analysed 176 consecutive patients with ... ...

    Abstract IgM monoclonal gammopathies of undetermined significance (IgM MGUS) are associated with a risk of progression to Waldenström macroglobulinaemia (WM) or other lymphoproliferative disorders (LPD) of 1-2% per year. We analysed 176 consecutive patients with IgM MGUS to evaluate risk factors for progression. With a median follow-up of 83 months (1214 person-years), 15 patients (8·5%) progressed to WM (n = 14) or marginal zone lymphoma (n = 1). The rate of progression was 1·32% per year (95% confidence interval [CI] 0·80-2·20). The serum monoclonal protein concentration and the MYD88 mutation were independent risk factors for progression (Hazard ratio [HR] 23·3, 95% CI 2·0-273·3, P = 0·012 and HR 24·4, 95% CI 2·2-275·3, P = 0·010, respectively). The cumulative incidence of progression, while considering death as a competing event, was 11·6% at 5 years and 38·0% at 10 years in MYD88-mutated patients with a serum monoclonal protein of 10 g/l or higher, as compared with 0% at 5 years and 1·1% at 10 years for patients with none or one risk factor. This risk-stratification model is able to identify a subset of patients with IgM MGUS at high risk of progression to WM or LPD who deserve a lifelong follow-up.
    MeSH term(s) Adult ; Aged ; Disease Progression ; Female ; Humans ; Immunoglobulin M ; Lymphoproliferative Disorders/etiology ; Male ; Middle Aged ; Monoclonal Gammopathy of Undetermined Significance/blood ; Monoclonal Gammopathy of Undetermined Significance/diagnosis ; Monoclonal Gammopathy of Undetermined Significance/pathology ; Mutation ; Myeloid Differentiation Factor 88/genetics ; Myeloma Proteins/analysis ; Risk Assessment/methods ; Risk Factors ; Waldenstrom Macroglobulinemia/etiology
    Chemical Substances Immunoglobulin M ; Myeloid Differentiation Factor 88 ; Myeloma Proteins ; multiple myeloma M-proteins
    Language English
    Publishing date 2019-07-05
    Publishing country England
    Document type Journal Article
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.16086
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.

    Gotti, Manuel / Sciarra, Roberta / Pulsoni, Alessandro / Merli, Francesco / Luminari, Stefano / Zerbi, Caterina / Trentin, Livio / Re, Alessandro / Rusconi, Chiara / Viviani, Simonetta / Rossi, Andrea / Cocito, Federica / Botto, Barbara / Meli, Erika / Pinto, Antonello / Dogliotti, Irene / Gini, Guido / Puccini, Benedetta / Ricci, Francesca /
    Nassi, Luca / Fabbri, Alberto / Liberati, Anna Marina / Merli, Michele / Filippi, Andrea Riccardo / Bonfichi, Maurizio / Zoboli, Valentina / Tartaglia, Germana / Annechini, Giorgia / D'Elia, Gianna Maria / Del Giudice, Ilaria / Alvarez, Isabel / Visentin, Andrea / Pravato, Stefano / Dalceggio, Daniela / Pagani, Chiara / Ferrari, Silvia / Cristinelli, Caterina / Lazic, Tanja / Ferretti, Virginia Valeria / Ricardi, Umberto / Arcaini, Luca

    HemaSphere

    2023  Volume 7, Issue 4, Page(s) e837

    Abstract: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare entity whose neoplastic cells retain a B-cell phenotype with expression of CD20. Radiotherapy is recommended for favorable stage IA disease while for other stages guidelines suggest ... ...

    Abstract Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare entity whose neoplastic cells retain a B-cell phenotype with expression of CD20. Radiotherapy is recommended for favorable stage IA disease while for other stages guidelines suggest therapeutic strategies similar to those used for classic HL. The role of rituximab, although quite widespread, is not completely elucidated. We retrospectively analyzed baseline characteristics of 308 consecutive patients with NLPHL diagnosed in 19 Italian centers from 2000 to 2018. With a median follow-up of 8.4 years (interquartile range: 4.5-12.4) for treated patients, median overall survival (OS) was not reached and estimated 5-year OS was 97.8% and 5-year progression-free survival (PFS) was 84.5%. Five-year cumulative incidence of histological transformation was 1.4%, 95% confidence interval (CI), 0.5%-3.8%. After adjusting for lymphocyte count, splenic involvement, bulky disease and B symptoms (fever, drenching night sweats, unintentional loss >10% of body weight within the preceding 6 months), patients with stage II or more showed superior PFS with immunochemotherapy in comparison to chemotherapy alone (hazard ratio = 0.4, 95% CI, 0.2-0.8;
    Language English
    Publishing date 2023-04-04
    Publishing country United States
    Document type Journal Article
    ISSN 2572-9241
    ISSN (online) 2572-9241
    DOI 10.1097/HS9.0000000000000837
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.

    Rattotti, Sara / Ferretti, Virginia Valeria / Rusconi, Chiara / Rossi, Andrea / Fogazzi, Stefano / Baldini, Luca / Pioltelli, Pietro / Balzarotti, Monica / Farina, Lucia / Ferreri, Andrés J M / Laszlo, Daniele / Speziale, Valentina / Varettoni, Marzia / Sciarra, Roberta / Morello, Lucia / Tedeschi, Alessandra / Frigeni, Marco / Defrancesco, Irene / Zerbi, Caterina /
    Flospergher, Elena / Nizzoli, Maria Elena / Morra, Enrica / Arcaini, Luca

    Hematological oncology

    2019  Volume 37, Issue 2, Page(s) 160–167

    Abstract: Chronic hepatitis C virus (HCV) infection is related with an increased risk of non-Hodgkin lymphomas (NHL). In indolent subtypes, regression of NHL was reported after HCV eradication with antiviral therapy (AT). In 2008 in Lombardy, a region of Northern ... ...

    Abstract Chronic hepatitis C virus (HCV) infection is related with an increased risk of non-Hodgkin lymphomas (NHL). In indolent subtypes, regression of NHL was reported after HCV eradication with antiviral therapy (AT). In 2008 in Lombardy, a region of Northern Italy, the "Rete Ematologica Lombarda" (REL, Hematology Network of Lombardy-Lymphoma Workgroup) started a prospective multicenter observational cohort study on NHL associated with HCV infection, named "Registro Lombardo dei Linfomi HCV-positivi" ("Lombardy Registry of HCV-associated non-Hodgkin lymphomas"). Two hundred fifty patients with a first diagnosis of NHL associated with HCV infection were enrolled; also in our cohort, diffuse large B cell lymphoma (DLBCL) and marginal zone lymphoma (MZL) are the two most frequent HCV-associated lymphomas. Two thirds of patients had HCV-positivity detection before NHL; overall, NHL was diagnosed after a median time of 11 years since HCV survey. Our data on eradication of HCV infection were collected prior the recent introduction of the direct-acting antivirals (DAAs) therapy. Sixteen patients with indolent NHL treated with interferon-based AT as first line anti-lymphoma therapy, because of the absence of criteria for an immediate conventional treatment for lymphoma, had an overall response rate of 90%. After a median follow-up of 7 years, the overall survival (OS) was significantly longer in indolent NHL treated with AT as first line (P = 0.048); this confirms a favorable outcome in this subset. Liver toxicity was an important adverse event after a conventional treatment in 20% of all patients, in particular among DLBCL, in which it is more frequent the coexistence of a more advanced liver disease. Overall, HCV infection should be consider as an important co-pathology in the treatment of lymphomas and an interdisciplinary approach should be always considered, in particular to evaluate the presence of fibrosis or necroinflammatory liver disease.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Disease-Free Survival ; Female ; Follow-Up Studies ; Hepacivirus ; Hepatitis C, Chronic/diagnosis ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/mortality ; Humans ; Interferons/administration & dosage ; Italy/epidemiology ; Lymphoma, Non-Hodgkin/diagnosis ; Lymphoma, Non-Hodgkin/drug therapy ; Lymphoma, Non-Hodgkin/mortality ; Male ; Middle Aged ; Prospective Studies ; Survival Rate
    Chemical Substances Interferons (9008-11-1)
    Language English
    Publishing date 2019-02-22
    Publishing country England
    Document type Clinical Trial ; Journal Article ; Multicenter Study
    ZDB-ID 604884-5
    ISSN 1099-1069 ; 0278-0232
    ISSN (online) 1099-1069
    ISSN 0278-0232
    DOI 10.1002/hon.2575
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV.

    Zappasodi, Patrizia / Cattaneo, Chiara / Valeria Ferretti, Virginia / Mina, Roberto / José María Ferreri, Andrés / Merli, Francesco / Oberti, Margherita / Krampera, Mauro / Romano, Alessandra / Zerbi, Caterina / Ferrari, Jacqueline / Cavo, Michele / Salvini, Marco / Bertù, Lorenza / Stefano Fracchiolla, Nicola / Marchesi, Francesco / Massaia, Massimo / Marasco, Vincenzo / Cairoli, Roberto /
    Maria Scattolin, Anna / Maria Vannucchi, Alessandro / Gambacorti-Passerini, Carlo / Musto, Pellegrino / Gherlinzoni, Filippo / Cuneo, Antonio / Pinto, Antonello / Trentin, Livio / Bocchia, Monica / Galimberti, Sara / Coviello, Elisa / Chiara Tisi, Maria / Morotti, Alessandro / Falini, Brunangelo / Turrini, Mauro / Tafuri, Agostino / Billio, Atto / Gentile, Massimo / Massimo Lemoli, Roberto / Venditti, Adriano / Giovanni Della Porta, Matteo / Lanza, Francesco / Rigacci, Luigi / Tosi, Patrizia / Mohamed, Sara / Corso, Alessandro / Luppi, Mario / Giuliani, Nicola / Busca, Alessandro / Pagano, Livio / Bruno, Raffaele / Antonio Grossi, Paolo / Corradini, Paolo / Passamonti, Francesco / Arcaini, Luca

    Hematological oncology

    2022  Volume 40, Issue 5, Page(s) 846–856

    Abstract: The impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a ... ...

    Abstract The impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID-19. Among 1741 HM patients with COVID-19, 134 (7.7%) had 185 SI, with a 1-month cumulative incidence of 5%. Median time between COVID-19 diagnosis and SI was 16 days (IQR: 5-36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson Comorbidity Index 5 vs. 4, p < 0.001), higher frequency of critical COVID-19 (19.5% vs. 11.5%, p = 0.046), and more frequently not in complete remission (75% vs. 64.7% p = 0.024). Blood and bronchoalveolar lavage were the main sites of isolation for SI. Etiology of infections was bacterial in 80% (n = 148) of cases, mycotic in 9.7% (n = 18) and viral in 10.3% (n = 19); polymicrobial infections were observed in 24 patients (18%). Escherichia coli represented most of Gram-negative isolates (18.9%), while coagulase-negative Staphylococci were the most frequent among Gram-positive (14.2%). The 30-day mortality of patients with SI was higher when compared to patients without SI (69% vs. 15%, p < 0.001). The occurrence of SI worsened COVID-19 outcome in HM patients. Timely diagnosis and adequate management should be considered to improve their prognosis.
    MeSH term(s) Humans ; Aged ; Coinfection ; COVID-19/complications ; COVID-19 Testing ; Hematologic Neoplasms/complications ; Lymphoma
    Language English
    Publishing date 2022-08-12
    Publishing country England
    Document type Multicenter Study ; Journal Article
    ZDB-ID 604884-5
    ISSN 1099-1069 ; 0278-0232
    ISSN (online) 1099-1069
    ISSN 0278-0232
    DOI 10.1002/hon.3048
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top